Mar 28, 2023
Highlights include the company’s significant progress in 2022 to create a more sustainable R&D model and advance potential new medicines to patients Salt Lake City , March 28, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology
Mar 01, 2023
SALT LAKE CITY , March 01, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Morgan Stanley Technology, Media & Telecom
Feb 01, 2023
SALT LAKE CITY , Feb. 1, 2023 /PRNewswire/ --  Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference:     SVB Securities Global Biopharma Conference — February 14
Dec 20, 2022
SALT LAKE CITY , Dec. 20, 2022 /PRNewswire/ --  Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences:     41st Annual J.P.
Nov 02, 2022
SALT LAKE CITY, Nov. 2, 2022 / PRNewswire / --  Recursion  (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences: Credit Suisse 31st Annual Healthcare Conference — 
Displaying 31 - 40 of 94